Headache Archive

People who experience chronic migraine headaches may benefit from treatment with botulimun neurotoxin (Botox), though other treatments such as medication are usually tried first.

A thunderclap headache is a sudden, extremely severe headache associated with several possible causes. It’s considered a medical emergency and should be treated as soon as possible.

 Image: © miya227/Getty Images

In the journals

Adults who sleep only six hours per night may have a higher chance of being dehydrated, compared with those who sleep longer, according to recent research published online Nov. 5, 2018, by the journal Sleep. The findings suggest that some of the symptoms of inadequate sleep, such as fatigue, fuzzy thinking, and headache in the morning, may be due to dehydration.

Researchers looked at the risk of dehydration in approximately 20,000 U.S. and Chinese adults. In both populations, people who reported sleeping six or fewer hours had up to a 59% higher risk of dehydration compared with those who slept seven to eight hours on a regular basis. The researchers speculated that the finding may reflect the nightly rhythm of a hormone called vasopressin. During sleep, the pituitary gland in the brain uses vasopressin to signal the kidneys to retain fluid in the body rather than excreting it through urine.

News briefs

Are you taking a medication that has depression or suicidal thinking as a potential side effect? One or both risks have been linked to use of more than 200 prescription and over-the-counter pills, including medicines that treat high blood pressure, heartburn, pain, and headaches. The more of these drugs you use, the higher the likelihood that you'll experience depression, suggests a study published June 12, 2018, in The Journal of the American Medical Association. Working with five surveys conducted over a nine-year period, researchers evaluated health information from 26,192 adults. About 37% of them reported taking such medications. Of individuals taking three or more of the medications with depression as a possible side effect, about 15% reported depression, compared with about 5% in people not using those medications. Even for people already taking an antidepressant, the addition of one or more of the identified medicines was linked to higher rates of depression. This study was based on surveys, so it didn't prove that the medications caused the reported depression. Nonetheless, if you think you're depressed (and have symptoms such as apathy, hopelessness, changes in sleep or eating habits, and persistent fatigue), ask your doctor if any of the medicines you are taking may be responsible.

Image: © Tero Vesalainen | GettyImages

News briefs

Encouraging news for people who suffer with migraines: in May, the FDA approved erenumab (Aimovig), the first medication aimed at preventing these debilitating headaches. Current medications to treat migraines were actually designed to control other conditions, such as seizures or an irregular heartbeat; their side effects (like sexual dysfunction and fuzzy thinking) often cause people to skip treatment. Erenumab offers a new approach. Injected once a month, it works by blocking a molecule (calcitonin gene-related peptide) involved in migraine attacks, and compared with other drugs, it appears to have fewer side effects (primarily constipation and injection site reactions). "This drug is for people who have more than four migraines per month, but it won't take migraines away entirely," says Dr. Gad Marshall, a neurologist at Harvard-affiliated Brigham and Women's Hospital. Clinical trials suggest it can reduce frequency by one or two migraines per month, or even more in some people. "For people with frequent debilitating migraines it could be a game changer," says Dr. Lee Schwamm, a neurologist at Harvard-affiliated Massachusetts General Hospital. "But erenumab is expensive, and it will take time to find out if it's effective and safe over the long term."

In the journals

 Image: © Wavebreakmedia/Getty Images

Migraine sufferers may be able to prevent future attacks with a new medication called galcanezumab, suggests a study published online Dec. 18, 2017, by JAMA Neurology. Currently, there are five FDA-approved drugs for migraines, but none were designed specifically for treating attacks or addressing the mechanisms at work.

In comparison, galcanezumab works to suppress the activity of calcitonin gene–related peptide (CGRP) in people. That molecule is believed to play an integral role in migraines and cluster headaches.